Elangovan A, Shah R, Ali SM, Katz J, Cooper GS. High burden of obesity and low rates of weight loss pharmacotherapy in inflammatory bowel disease: 10-year trend. Crohn’s & Colitis 360. 2023;5(2):otad007.
Kim MK, Shin SH, Lee C-H, Kim S, Kim JW, Lee S, et al. Temporal trends in obesity and its prognostic impact in Korean patients with inflammatory bowel disease. J Gastroenterol. 2025;60(5):583–92.
Khalili H, Ananthakrishnan AN, Konijeti GG, Higuchi LM, Fuchs CS, Richter JM, Chan AT. Measures of obesity and risk of crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2015;21(2):361–8.
Chan SS, Chen Y, Casey K, Olen O, Ludvigsson JF, Carbonnel F, et al. Obesity is associated with increased risk of crohn’s disease, but not ulcerative colitis: a pooled analysis of five prospective cohort studies. Clin Gastroenterol Hepatol. 2022;20(5):1048–58.
Bhagavathula AS, Clark CCT, Rahmani J, Chattu VK. Impact of body mass index on the development of inflammatory bowel disease: A systematic review and Dose-Response analysis of 15.6 million participants. Healthc (Basel). 2021;9(1):35
He Z, Fu T, Lu S, Sun Y, Zhang Y, Shi W, et al. Adiposity as a risk factor for inflammatory bowel disease and the mediating effect of metabolic and inflammatory status: a population-based cohort study. United Eur Gastroenterol J. 2023;11(10):973–84.
Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14(2):110–21.
Dai Z-h, Xu X-t, Ran Z-h. Associations between obesity and the effectiveness of anti–tumor necrosis factor-α agents in inflammatory bowel disease patients: a literature review and meta-analysis. Ann Pharmacother. 2020;54(8):729–41.
El-Dallal M, Stein DJ, Raita Y, Feuerstein JD. The impact of obesity on hospitalized patients with ulcerative colitis. Ann Gastroenterol. 2021;34(2):196.
Dahiya DS, Kichloo A, Wani F, Singh J, Solanki D, Shaka H. A nationwide analysis on the influence of obesity in inflammatory bowel disease hospitalizations. Intest Res. 2022;20(3):342–9.
Gu P, Luo J, Kim J, Paul P, Limketkai B, Sauk JS, et al. Effect of obesity on risk of hospitalization, surgery, and serious infection in biologic-treated patients with inflammatory bowel diseases: a CA-IBD cohort study. Am J Gastroenterol. 2022;117(10):1639–47.
Shneyderman M, Freid H, Kohler D, Peraza J, Haskey N, Abbott E, et al. Management of overweight and obesity in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2024;20(12):712.
Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of Glucagon-Like peptide 1 receptor agonists. Adv Ther. 2021;38(6):2821–39.
Arvanitakis K, Koufakis T, Popovic D, Maltese G, Mustafa O, Doumas M, et al. GLP-1 receptor agonists in obese patients with inflammatory bowel disease: from molecular mechanisms to clinical considerations and practical recommendations for safe and effective use. Curr Obes Rep. 2023;12(2):61–74.
Gravina AG, Pellegrino R, Izzo M, De Costanzo I, Imperio G, Landa F, et al. Relevance of Glucagon-Like peptide 1 (GLP-1) in inflammatory bowel diseases: a narrative review. Curr Issues Mol Biol. 2025;47(5):383.
Wells GSOCD, Peterson J, Welch VA, Losos M, Tugwel P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
Anderson SR, Ayoub M, Coats S, McHenry S, Tan T, Deepak P. Safety and effectiveness of Glucagon-like Peptide-1 receptor agonists in inflammatory bowel disease. Am J Gastroenterol. 2025;120(5):1152–5.
Ramos Belinchón C, MartÃnez-Lozano H, Serrano Moreno C, Hernández Castillo D, Lois Chicharro P, Ferreira Ocampo P, et al. Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2024;116(9):478–83.
St-Pierre J, Klein J, Choi NK, Fear E, Pannain S, Rubin DT. Efficacy and safety of GLP-1 agonists on metabolic parameters in non-diabetic patients with inflammatory bowel disease. Dig Dis Sci. 2024;69(12):4437–45.
Sehgal P, Lewis JD, Pickett-Blakely O, Nandi N, Bewtra M, Lichtenstein GR. Safety and clinical effectiveness of GLP1 receptor agonists in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2025;23(8):1453-4.e3.
Desai A, Khataniar H, Hashash JG, Farraye FA, Regueiro M, Kochhar GS. Effectiveness and safety of semaglutide for weight loss in patients with inflammatory bowel disease and obesity. Inflamm Bowel Dis. 2025;31(3):696–705.
Clarke L, Passam RT, Falahee B, Jirapinyo P, Allegretti JR, Kelly CR. Tolerability and effectiveness of Glucagon-Like Peptide-1 receptor agonists in patients with inflammatory bowel disease. Dig Dis Sci. 2025;70(7):2426–32.
Levine I, Sekhri S, Schreiber-Stainthorp W, Locke B, Delau O, Elhawary M, et al. GLP-1 receptor agonists confer no increased rates of IBD exacerbation among patients with IBD. Inflamm Bowel Dis. 2025;31(2):467–75.
Weng J, Alizadeh M, Friedman S. Glucagon-Like Peptide-1 receptor agonist therapy does not increase Gastrointestinal adverse events in patients with inflammatory bowel disease. Dig Dis Sci. 2025;70(10):3476–84.
Peraza J, Abbott E, Shneyderman M, Kornbluth A, Raman M, Gold S. The rising epidemic of obesity in patients with inflammatory bowel disease. Curr Treat Options Gastroenterol. 2024;22(3):134–44.
Kim SK, Lee HS, Kim BJ, Park JH, Hwang SW, Yang DH, et al. The clinical features of inflammatory bowel disease in patients with obesity. Can J Gastroenterol Hepatol. 2021;2021:9981482.
Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. The increasing weight of crohn’s disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. Inflamm Bowel Dis. 2013;19(13):2949–56.
Bischoff SC, Barazzoni R, Busetto L, Campmans-Kuijpers M, Cardinale V, Chermesh I, et al. European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline. United Eur Gastroenterol J. 2022;10(7):663–720.
Van Der Sloot KW, Joshi AD, Bellavance DR, Gilpin KK, Stewart KO, Lochhead P, et al. Visceral Adiposity, genetic Susceptibility, and risk of complications among individuals with crohn’s disease. Inflamm Bowel Dis. 2017;23(1):82–8.
Thin L, Teh WL. GLP-1R agonists and their therapeutic potential in inflammatory bowel disease and other Immune-Mediated inflammatory diseases, a systematic review of the literature. Biomedicines. 2025;13(5):1128.
Vahora I, Moparthi KP, Al Rushaidi MT, Muddam MR, Obajeun OA, Abaza A, et al. Efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss management in non-diabetic patients. Cureus. 2024;16(7):e65050.
Bayoumy AB, Clarke LM, Deepak P, Desai A, Sehgal P, Gorelik Y, Bar-Yoseph H, Villumsen M, Mulder CJJ, Stenvers DJ, Tushuizen ME, de Boer NKH. Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) and the Clinical Outcomes of Inflammatory Bowel Disease (IBD): A Systematic Review and Meta-analysis. J Crohns Colitis. 2025:jjaf181. https://doi.org/10.1093/ecco-jcc/jjaf181. Epub ahead of print. PMID:41071055.
Yang M, Huo Y, Liu Z, Bai G, He D, Zhang L. The role of GLP-1 receptor agonists in IBD-related surgery and IBD-related complications of inflammatory bowel disease among patients with metabolic comorbidities: a systematic review and meta-analysis. Front Med Lausanne. 2025;12:1621958.
Wong HJ, Sim B, Teo YH, Teo YN, Chan MY, Yeo LLL, et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care. 2025;48(2):292–300.
Liu Y, Ruan B, Jiang H, Le S, Liu Y, Ao X, et al. The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Am J Clin Nutr. 2023;118(3):614–26.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15(1):15–27.
Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:2042018821997320.
Gorelik Y, Ghersin I, Lujan R, Shlon D, Loewenberg Weisband Y, Ben-Tov A, et al. GLP-1 analog use is associated with improved disease course in inflammatory bowel disease: A report from the Epi-IIRN. J Crohns Colitis. 2025;19(4):jjae160.
Desai A, Petrov J, Hashash JG, Patel H, Brahmbhatt B, Kochhar GS, Farraye FA. Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;60(5):620–32.
Nielsen J, Friedman S, Nørgård BM, Knudsen T, Kjeldsen J, Wod M. Glucagon-like peptide 1 receptor agonists are not associated with an increased risk of ileus or intestinal obstruction in patients with inflammatory bowel disease-a Danish nationwide cohort study. Inflamm Bowel Dis. 2025;31(7):1961–5.
Villumsen M, Schelde AB, Jimenez-Solem E, Jess T, Allin KH. GLP-1 based therapies and disease course of inflammatory bowel disease. E Clin Med. 2021;37:100979.
Gala K, Tome J, Krall M, Tian D, League JB, Vargas EJ, et al. Quality of bowel Preparation for colonoscopy in patients on glucagon-like peptide-1 receptor agonists. Gastrointest Endosc. 2025;101(5):1068–e721.
Beran A, Nayfeh T, Akhras A, Ramai D, Mohamed M, Guardiola JJ, et al. Effect of glucagon-like peptide-1 receptor agonists on bowel preparation for colonoscopy: a systematic review and meta-analysis. Am J Gastroenterol. 2025;120(7):1653–6.
Abu-Freha N, Yitzhak A, Shirin H, Nevo-Shor A, Abu-Jaffar J, Abu-Rafe S, et al. Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel Preparation for colonoscopy. Endoscopy. 2025;57(2):126–33.
Al-Dwairi A, Alqudah TE, Al-Shboul O, Alqudah M, Mustafa AG, Alfaqih MA. Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro. J Inflamm Res. 2018;11:95–109.
Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209.
Chen J, Mei A, Liu X, Braunstein Z, Wei Y, Wang B, et al. Glucagon-like peptide-1 receptor regulates macrophage migration in monosodium urate-induced peritoneal inflammation. Front Immunol. 2022;13:772446.
Bang-Berthelsen CH, Holm TL, Pyke C, Simonsen L, Søkilde R, Pociot F, et al. GLP-1 induces barrier protective expression in brunner’s glands and regulates colonic inflammation. Inflamm Bowel Dis. 2016;22(9):2078–97.
Lucotti P, Lovati E, Lenti MV, Valvo B, Sprio E, Aronico N, et al. Abnormal post-prandial glucagon-like peptide release in patients with Crohn’s disease. Clin Res Hepatol Gastroenterol. 2021;45(4):101533.
Mahmoud M, Syn WK. Impact of obesity and metabolic syndrome on IBD outcomes. Dig Dis Sci. 2024;69(8):2741–53.
Sehgal P, Su S, Zech J, Nobel Y, Luk L, Economou I, et al. Visceral adiposity independently predicts time to flare in inflammatory bowel disease but body mass index does not. Inflamm Bowel Dis. 2024;30(4):594–601.
Krugliak Cleveland N, St-Pierre J, Kellar A, Rubin DT. Clinical application of intestinal ultrasound in inflammatory bowel disease. Curr Gastroenterol Rep. 2024;26(2):31–40.